DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new $400 million fund, it told STAT exclusively.
This is the third fund DCVC Bio has raised. It came in ahead of the original $350 million goal, according to executives.
The announcement makes DCVC Bio one of a select number of biotech VCs to raise new pools of capital this year. Biotech investors raised 53 funds last year and 85 funds in 2022, but halfway through this year, they had raised just 15 funds. (Both ARCH Venture Partners and Flagship Pioneering have announced new fundraisings since then.)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in